MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use

J Nucl Med. 2005 Jan:46 Suppl 1:55S-61S.

Abstract

Nuclear imaging techniques such as bone scans, metaiodobenzylguanidine (MIBG) scans, and (111)In-diethylenetriaminepentaacetic acid-octreotide scans have greatly increased the sensitivity and specificity of both diagnostic and follow-up protocols for pediatric solid tumors. Molecular targets that are specific for certain pediatric tumors are now being developed. Targets include cell membrane receptors targeted by specific ligands, subcellular organelles targeted by false transmitters, and cellular proteins targeted by antibodies. This review focuses on the use of MIBG (which is a false transmitter) and octreotide (which is a ligand for G protein receptor) in the diagnosis and treatment of solid tumors that affect children and young adults.

Publication types

  • Review

MeSH terms

  • 3-Iodobenzylguanidine / adverse effects
  • 3-Iodobenzylguanidine / therapeutic use*
  • Animals
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Humans
  • Infant
  • Infant, Newborn
  • Neuroblastoma / diagnostic imaging*
  • Neuroblastoma / radiotherapy*
  • Octreotide / analogs & derivatives*
  • Patient Selection
  • Pentetic Acid / analogs & derivatives*
  • Practice Guidelines as Topic
  • Practice Patterns, Physicians' / trends
  • Radiation Injuries / etiology
  • Radiation Injuries / prevention & control
  • Radionuclide Imaging
  • Radiopharmaceuticals / adverse effects
  • Somatostatin / analogs & derivatives
  • Treatment Outcome

Substances

  • Radiopharmaceuticals
  • SDZ 215-811
  • 3-Iodobenzylguanidine
  • Somatostatin
  • Pentetic Acid
  • Octreotide